EMUGROBART
UNII INA01972XV

Substance Identification & Data

This profile provides standardized clinical and technical data for Emugrobart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) INA01972XV.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2922218-19-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

INA01972XV

CAS Registry Number

2922218-19-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EMUGROBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211774

National Cancer Institute reference terminology for clinical and research data.

INN ID

13238

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Emugrobart

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Emugrobart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Emugrobart

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV3-66*01 (69.1%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH2 E12, M14, G1v86 CH2 Y1.3, D2, I26, K115, G1v87 V14, P90, G1v88 CH2 R94, CH3 R1.2, G1v89 CH3 T116, R118, G1v78-1 CH3 L107, A114, T116 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>Y (236), P2>D (240), T14>V (252), V26>I (266), T90>P (309), Q94>R (313), A115>K (332) (233-342), CH3 E12 (358), M14 (360), P1.2>R (345), M107>L (430), N114>A (436), Y116>T (438), Q118>R (440), S120>E (442) (343-447), CHS G1>del, K2>del) (120-447)], (222-217')-disulfide with L-kappa light chain humanized (1'-217') [VKAPPA (Homo sapiens IGKV3D-7*01 (77.7%) -IGKJ2*02 (90.0%) L124>V (107'), CDR-IMGT [8.3.10] (27'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (156'), V101 (194')) (111'-217')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DXB11, glycoform alfa

Immunoglobulin G1 [236-tyrosine,240-aspartic acid,252-valine,266-isoleucine,309-proline,313-arginine,332-lysine,345-arginine,430-leucine,436-alanine,438-threonine,440-arginine,442-glutamic acid,de-448-glycine,de-449-lysine], anti-(human latent growth differentiation factor 8) (human-Oryctolagus cuniculus monoclonal RO7204239 γ1-chain), disulfide with human-Oryctolagus cuniculus monoclonal RO7204239 κ-chain, dimer

emugrobart [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody;